Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with a high mortality rate. While chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections represent the leading risk factors worldwide, the spreading of metabolic disorders, such as diabetes, obesity and non-alcoholic fatty liver disease (NAFLD) justifies the increasing attention on their oncogenic mechanisms. This review discusses about the main pathogenic mechanisms implicated in occurrence of HCC in presence of viral and metabolic diseases. Additionally, it points to the importance of clinical surveillance for those patients considered at risk of HCC and highlights the strategical role of serum markers, such as alfa-fetoprotein (αFP) and Protein Induced by Vitamin K Absence or Antagonist II (PIVKA-II), which, in association to a strictly instrumental follow-up, contribute to the early detection of hepatic nodules with a better prognosis for affected patients.
KeywordsHepatocellular Carcinoma (HCC)Hepatitis B Virus (HBV)Hepatitis C Virus (HCV)Non-Alcoholic Fatty Liver Disease (NAFLD)Non-Alcoholic Steatohepatitis (NASH)Insulin Resistance (IR)Type 2 Diabetes Mellitus (T2DM)Intestinal MicrobiotaVisceral ObesityAlfa-Fetoprotein (αFP)Protein Induced by Vitamin K Absence or Antagonist II (PIVKA-II)
Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M. and Matrisian, L.M. (2014) Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research, 74, 2913-2921. https://doi.org/10.1158/0008-5472.CAN-14-0155
Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA Cancer Journal of Clinicians, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386. https://doi.org/10.1002/ijc.29210
Mittal, S. and El-Serag, H.B. (2013) Epidemiology of Hepatocellular Carcinoma: Consider the Population. Journal of Clinical Gastroenterology, 47, S2-S6. https://doi.org/10.1097/MCG.0b013e3182872f29
Ozakyol, A. (2017) Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). Journal of Gastrointestinal Cancer, 48, 238-240. https://doi.org/10.1007/s12029-017-9959-0
Donato, F., Tagger, A., Gelatti, U., Parrinello, G., Boffetta, P., Albertini, A., et al. (2002) Alcohol and Hepatocellular Carcinoma: The Effect of Lifetime Intake and Hepatitis Virus Infections in Men and Women. American Journal of Epidemiology, 155, 323-331. https://doi.org/10.1093/aje/155.4.323
Fattovich, G., Stroffolini, T., Zagni, I. and Donato, F. (2004) Hepatocellular Carcinoma in Cirrhosis: Incidence and Risk Factors. Gastroenterology, 127, S35-S50. https://doi.org/10.1053/j.gastro.2004.09.014
Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G. and Ott, J.J. (2015) Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review of Data Published between 1965 and 2013. Lancet, 386, 1546-1555. https://doi.org/10.1016/S0140-6736(15)61412-X
Shi, J., Zhu, L., Liu, S. and Xie, W.F. (2005) A Meta-Analysis of Case-Control Studies on the Combined Effect of Hepatitis B and C Virus Infections in Causing Hepatocellular Carcinoma in China. British Journal of Cancer, 92, 607-612. https://doi.org/10.1038/sj.bjc.6602333
Chan, H.L., Tse, C.H., Mo, F., Koh, J., Wong, V.W., Wong, G.L., et al. (2008) High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated with Increased Risk of Hepatocellular Carcinoma. Journal of Clinical Oncology, 26, 177-182. https://doi.org/10.1200/JCO.2007.13.2043
Chu, Y.J., Yang, H.I., Wu, H.C., Liu, J., Wang, L.Y., Lu, S.N., et al. (2017) Aflatoxin B1 Exposure Increases the Risk of Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Virus Carriers. International Journal of Cancer, 141, 711-720. https://doi.org/10.1002/ijc.30782
Chen, C.J., Yang, H.I. and Iloeje, U.H. (2009) Hepatitis B Virus DNA Levels and Outcomes in Chronic Hepatitis B. Hepatology, 49, S72-S84. https://doi.org/10.1002/hep.22884
Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., et al. (2012) Sodium Taurocholate Cotransporting Polypeptide Is a Functional Receptor for Human Hepatitis B and D Virus. Elife, 1, e00049. https://doi.org/10.7554/eLife.00049
Zeisel, M.B., Lucifora, J., Mason, W.S., Sureau, C., Beck, J., Levrero, M., et al. (2015) Towards an HBV Cure: State-of-The-Art and Unresolved Questions—Report of the ANRS Workshop on HBV Cure. Gut, 64, 1314-1326. https://doi.org/10.1136/gutjnl-2014-308943
Hsieh, A., Kim, H.S., Lim, S.O., Yu, D.Y. and Jung, G. (2011) Hepatitis B Viral X Protein Interacts with Tumor Suppressor Adenomatous Polyposis Coli to Activate Wnt/Beta-Catenin Signaling. Cancer Letters, 300, 162-172. https://doi.org/10.1016/j.canlet.2010.09.018
Kuo TC, Chao CC. Hepatitis B virus X protein prevents apoptosis of hepatocellular carcinoma cells by upregulating SATB1 and HURP expression. Biochem Pharmacol 2010 Oct 1;80(7):1093-1102.
Jung, S.Y. and Kim, Y.J. (2013) C-Terminal Region of HBx Is Crucial for Mitochondrial DNA Damage. Cancer Letters, 331, 76-83. https://doi.org/10.1016/j.canlet.2012.12.004
Ching, R.H.H., Sze, K.M.F., Lau, E.Y.T., Chiu, Y.T., Lee, J.M.F., Ng, I.O.L., et al. (2017) C-Terminal Truncated Hepatitis B Virus X Protein Regulates Tumorigenicity, Self-Renewal and Drug Resistance via STAT3/Nanog Signaling Pathway. Oncotarget, 8, 23507-23516. https://doi.org/10.18632/oncotarget.15183
Zhu, R., Mok, M.T., Kang, W., Lau, S.S., Yip, W.K., Chen, Y., et al. (2015) Truncated HBx-Dependent Silencing of GAS2 Promotes Hepatocarcinogenesis through Deregulation of Cell Cycle, Senescence and p53-Mediated Apoptosis. The Journal of Pathology, 237, 38-49. https://doi.org/10.1002/path.4554
Yip, W.K., Cheng, A.S., Zhu, R., Lung, R.W., Tsang, D.P., Lau, S.S., et al. (2011) Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. PLoS ONE, 6, e22888. https://doi.org/10.1371/journal.pone.0022888
Bozza, C., Cinausero, M., Iacono, D. and Puglisi, F. (2016) Hepatitis B and Cancer: A Practical Guide for the Oncologist. Critical Reviews in Oncology/Hematology, 98, 137-146.
Pattullo, V. (2016) Prevention of Hepatitis B Reactivation in the Setting of Immunosuppression. Clinical and Molecular Hepatology, 22, 219-237. https://doi.org/10.3350/cmh.2016.0024
Lok, A.S., Ward, J.W., Perrillo, R.P., McMahon, B.J. and Liang, T.J. (2012) Reactivation of Hepatitis B during Immunosuppressive Therapy: Potentially Fatal Yet Preventable. Annals of Internal Medicine, 156, 743-745. https://doi.org/10.7326/0003-4819-156-10-201205150-00013
Bessone, F. and Dirchwolf, M. (2016) Management of Hepatitis B Reactivation in Immunosuppressed Patients: An Update on Current Recommendations. World Journal of Hepatology, 8, 385-394. https://doi.org/10.4254/wjh.v8.i8.385
Yasunaka, T., Ikeda, F., Wada, N., Morimoto, Y., Fujioka, S., Toshimori, J., et al. (2016) Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients. Acta Medica Okayama, 70, 1-12.
Cho, H., Ahn, H., Lee, D.H., Lee, J.H., Jung, Y.J., Chang, Y., et al. (2018) Entecavir and Tenofovir Reduce Hepatitis B Virus-Related Hepatocellular Carcinoma Recurrence More Effectively than Other Antivirals. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.12855
Wang, J.P., Kao, F.Y., Wu, C.Y., Hung, Y.P., Chao, Y., Chou, Y.J., et al. (2015) Nucleos(t)ide Analogues Associated with a Reduced Risk of Hepatocellular Carcinoma in Hepatitis B Patients: A Population-Based Cohort Study. Cancer, 121, 1446-1455. https://doi.org/10.1002/cncr.29159
Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A. and Cacciapuoti, C. (2016) Global Epidemiology of Hepatitis C Virus Infection: An Up-Date of the Distribution and Circulation of Hepatitis C Virus Genotypes. World Journal of Gastroenterology, 22, 7824-7840. https://doi.org/10.3748/wjg.v22.i34.7824
Rehermann, B. and Nascimbeni, M. (2005) Immunology of Hepatitis B Virus and Hepatitis C Virus Infection. Nature Reviews Immunology, 5, 215-229. https://doi.org/10.1038/nri1573
El-Serag, H.B. (2011) Hepatocellular Carcinoma. The New England Journal of Medicine, 365, 1118-1127. https://doi.org/10.1056/NEJMra1001683
Wong, R.J., Aguilar, M., Cheung, R., Perumpail, R.B., Harrison, S.A., Younossi, Z.M., et al. (2015) Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease among Adults Awaiting Liver Transplantation in the United States. Gastroenterology, 148, 547-555. https://doi.org/10.1053/j.gastro.2014.11.039
Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., et al. (1998) Binding of Hepatitis C Virus to CD81. Science, 282, 938-941. https://doi.org/10.1126/science.282.5390.938
Sasaki, M., Yamauchi, K., Nakanishi, T., Kamogawa, Y. and Hayashi, N. (2003) In Vitro Binding of Hepatitis C Virus to CD81-Positive and -Negative Human Cell Lines. Journal of Gastroenterology and Hepatology, 18, 74-79. https://doi.org/10.1046/j.1440-1746.2003.02925.x
Meredith, L.W., Wilson, G.K., Fletcher, N.F. and McKeating, J.A. (2012) Hepatitis C Virus Entry: Beyond Receptors. Reviews in Medical Virology, 22, 182-193. https://doi.org/10.1002/rmv.723
Penin, F., Dubuisson, J., Rey, F.A., Moradpour, D. and Pawlotsky, J.M. (2004) Structural Biology of Hepatitis C Virus. Hepatology, 39, 5-19. https://doi.org/10.1002/hep.20032
Lee, Y.A., Wallace, M.C. and Friedman, S.L. (2015) Pathobiology of Liver Fibrosis: A Translational Success Story. Gut, 64, 830-841. https://doi.org/10.1136/gutjnl-2014-306842
Lemon, S.M. and McGivern, D.R. (2012) Is Hepatitis C Virus Carcinogenic? Gastroenterology, 142, 1274-1278. https://doi.org/10.1053/j.gastro.2012.01.045
Barazani, Y., Hiatt, J.R., Tong, M.J. and Busuttil, R.W. (2007) Chronic Viral Hepatitis and Hepatocellular Carcinoma. World Journal of Surgery, 31, 1243-1248. https://doi.org/10.1007/s00268-007-9041-3
Hino, O., Kajino, K., Umeda, T. and Arakawa, Y. (2002) Understanding the Hypercarcinogenic State in Chronic Hepatitis: A Clue to the Prevention of Human Hepatocellular Carcinoma. Journal of Gastroenterology, 37, 883-887. https://doi.org/10.1007/s005350200149
Henderson, N.C., Arnold, T.D., Katamura, Y., Giacomini, M.M., Rodriguez, J.D., McCarty, J.H., et al. (2013) Targeting of αv Integrin Identifies a Core Molecular Pathway That Regulates Fibrosis in Several Organs. Nature Medicine, 19, 1617-1624. https://doi.org/10.1038/nm.3282
El-Serag, H.B. (2012) Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, 142, 1264-1273. https://doi.org/10.1053/j.gastro.2011.12.061
Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T. and Jennings, L.W. (2010) Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology, 138, 513-521. https://doi.org/10.1053/j.gastro.2009.09.067
Calle, E.E. and Kaaks, R. (2004) Overweight, Obesity and Cancer: Epidemiological Evidence and Proposed Mechanisms. Nature Reviews Cancer, 4, 579-591. https://doi.org/10.1038/nrc1408
Roche, B., Coilly, A., Duclos-Vallee, J.C. and Samuel, D. (2018) The Impact of Treatment of Hepatitis C with DAAs on the Occurrence of HCC. Liver International, 38, 139-145. https://doi.org/10.1111/liv.13659
Lee, M.H., Yang, H.I., Lu, S.N., Jen, C.L., You, S.L., Wang, L.Y., et al. (2012) Chronic Hepatitis C Virus Infection Increases Mortality from Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study. The Journal of Infectious Diseases, 206, 469-477. https://doi.org/10.1093/infdis/jis385
Ioannou, G.N., Green, P.K. and Berry, K. (2017) HCV Eradication Induced by Direct-Acting Antiviral Agents Reduces the Risk of Hepatocellular Carcinoma. Journal of Hepatology.
Colombo, M. and Boccaccio, V. (2018) Hepatitis C Eradication with DAA and Risk of Liver Cancer Recurrence: The Debate Unrests. Journal of Viral Hepatitis.
Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. (2016) Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Journal of Hepatology, 65, 727-733. https://doi.org/10.1016/j.jhep.2016.06.015
Grandhe, S. and Frenette, C.T. (2017) Occurrence and Recurrence of Hepatocellular Carcinoma after Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Virus Infection. Gastroenterology & Hepatology, 13, 421-425.
Kozbial, K., Moser, S., Al-Zoairy, R., Schwarzer, R., Datz, C., Stauber, R., et al. (2017) Follow-Up of Sustained Virological Responders with Hepatitis C and Advanced Liver Disease after Interferon/Ribavirin-Free Treatment. Liver International.
Farazi, P.A. and DePinho, R.A. (2006) Hepatocellular Carcinoma Pathogenesis: From Genes to Environment. Nature Reviews Cancer, 6, 674-687. https://doi.org/10.1038/nrc1934
Lim, S.S., Vos, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H., et al. (2012) A Comparative Risk Assessment of Burden of Disease and Injury Attributable to 67 Risk Factors and Risk Factor Clusters in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. The Lancet, 380, 2224-2260. https://doi.org/10.1016/S0140-6736(12)61766-8
Galicia-Moreno, M. and Gutierrez-Reyes, G. (2014) The Role of Oxidative Stress in the Development of Alcoholic Liver Disease. Revista de Gastroenterología de México, 79, 135-144. https://doi.org/10.1016/j.rgmx.2014.03.001
Ghouri, Y.A., Mian, I. and Rowe, J.H. (2017) Review of Hepatocellular Carcinoma: Epidemiology, Etiology, and Carcinogenesis. Journal of Carcinogenesis, 16, 1. https://doi.org/10.4103/jcar.JCar_9_16
Hutchinson, S.J., Bird, S.M. and Goldberg, D.J. (2005) Influence of Alcohol on the Progression of Hepatitis C Virus Infection: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 3, 1150-1159.
Magnussen, A. and Parsi, M.A. (2013) Aflatoxins, Hepatocellular Carcinoma and Public Health. World Journal of Gastroenterology, 19, 1508-1512. https://doi.org/10.3748/wjg.v19.i10.1508
Saad-Hussein, A., Taha, M.M., Beshir, S., Shahy, E.M., Shaheen, W. and Elhamshary, M. (2014) Carcinogenic Effects of Aflatoxin B1 among Wheat Handlers. International Journal of Occupational and Environmental Health, 20, 215-219. https://doi.org/10.1179/2049396714Y.0000000069
Kew, M.C. (2013) Aflatoxins as a Cause of Hepatocellular Carcinoma. Journal of Gastrointestinal and Liver Diseases, 22, 305-310.
Qi, L.N., Bai, T., Chen, Z.S., Wu, F.X., Chen, Y.Y., De, X.B., et al. (2015) The p53 Mutation Spectrum in Hepatocellular Carcinoma from Guangxi, China: Role of Chronic Hepatitis B Virus Infection and Aflatoxin B1 Exposure. Liver International, 35, 999-1009. https://doi.org/10.1111/liv.12460
Hamid, A.S., Tesfamariam, I.G., Zhang, Y. and Zhang, Z.G. (2013) Aflatoxin B1-Induced Hepatocellular Carcinoma in Developing Countries: Geographical Distribution, Mechanism of Action and Prevention. Oncology Letters, 5, 1087-1092. https://doi.org/10.3892/ol.2013.1169
Kucukcakan, B. and Hayrulai-Musliu, Z. (2015) Challenging Role of Dietary Aflatoxin B1 Exposure and Hepatitis B Infection on Risk of Hepatocellular Carcinoma. Open Access Macedonian Journal of Medical Sciences, 3, 363-369. https://doi.org/10.3889/oamjms.2015.032
Liu, Y. and Wu, F. (2010) Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment. Environmental Health Perspectives, 118, 818-824.
Bellentani, S., Scaglioni, F., Marino, M. and Bedogni, G. (2010) Epidemiology of Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 28, 155-161. https://doi.org/10.1159/000282080
Said, A. and Ghufran, A. (2017) Epidemic of Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. World Journal of Clinical Oncology, 8, 429-436. https://doi.org/10.5306/wjco.v8.i6.429
Benedict, M. and Zhang, X. (2017) Non-Alcoholic Fatty Liver Disease: An Expanded Review. World Journal of Hepatology, 9, 715-732. https://doi.org/10.4254/wjh.v9.i16.715
Patel, V., Sanyal, A.J. and Sterling, R. (2016) Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Clinical Liver Disease, 20, 277-292. https://doi.org/10.1016/j.cld.2015.10.006
Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H. and Loomba, R. (2015) Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology, 13, 643-654. https://doi.org/10.1016/j.cgh.2014.04.014
Welzel, T.M., Graubard, B.I., Zeuzem, S., El-Serag, H.B., Davila, J.A. and McGlynn, K.A. (2011) Metabolic Syndrome Increases the Risk of Primary Liver Cancer in the United States: A Study in the SEER-Medicare Database. Hepatology, 54, 463-471. https://doi.org/10.1002/hep.24397
Marengo, A., Rosso, C. and Bugianesi, E. (2016) Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annual Review of Medicine, 67, 103-117. https://doi.org/10.1146/annurev-med-090514-013832
Chen, G., Ni, Y., Nagata, N., Xu, L. and Ota, T. (2016) Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 17, 1379. https://doi.org/10.3390/ijms17091379
Angulo, P. (2006) NAFLD, Obesity, and Bariatric Surgery. Gastroenterology, 130, 1848-1852. https://doi.org/10.1053/j.gastro.2006.03.041
Agosti, P., Sabba, C. and Mazzocca, A. (2018) Emerging Metabolic Risk Factors in Hepatocellular Carcinoma and Their Influence on the Liver Microenvironment. Biochimica et Biophysica Acta, 1864, 607-617. https://doi.org/10.1016/j.bbadis.2017.11.026
Siddique, A. and Kowdley, K.V. (2011) Insulin Resistance and Other Metabolic Risk Factors in the Pathogenesis of Hepatocellular Carcinoma. Clinical Liver Disease, 15, 281-296. https://doi.org/10.1016/j.cld.2011.03.007
Hardy, T., Oakley, F., Anstee, Q.M. and Day, C.P. (2016) Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology, 11, 451-496. https://doi.org/10.1146/annurev-pathol-012615-044224
Ibrahim, S.H., Hirsova, P. and Gores, G.J. (2018) Non-Alcoholic Steatohepatitis Pathogenesis: Sublethal Hepatocyte Injury as a Driver of Liver Inflammation. Gut, 67, 963-972. https://doi.org/10.1136/gutjnl-2017-315691
Hirsova, P., Ibrahim, S.H., Gores, G.J. and Malhi, H. (2016) Lipotoxic Lethal and Sublethal Stress Signaling in Hepatocytes: Relevance to NASH Pathogenesis. The Journal of Lipid Research, 57, 1758-1770. https://doi.org/10.1194/jlr.R066357
Krenkel, O. and Tacke, F. (2017) Liver Macrophages in Tissue Homeostasis and Disease. Nature Reviews Immunology, 17, 306-321. https://doi.org/10.1038/nri.2017.11
Heymann, F. and Tacke, F. (2016) Immunology in the Liver—From Homeostasis to Disease. Nature Reviews Gastroenterology & Hepatology, 13, 88-110. https://doi.org/10.1038/nrgastro.2015.200
Koyama, Y. and Brenner, D.A. (2017) Liver Inflammation and Fibrosis. Journal of Clinical Investigation, 127, 55-64. https://doi.org/10.1172/JCI88881
Sera, T., Sumii, T., Fujita, R. and Kudo, S. (2018) Effect of Shear Stress on the Migration of Hepatic Stellate Cells. In Vitro Cellular & Developmental Biology—Animal, 54, 11-22. https://doi.org/10.1007/s11626-017-0202-x
Sanyal, A., Poklepovic, A., Moyneur, E. and Barghout, V. (2010) Population-Based Risk Factors and Resource Utilization for HCC: US Perspective. Current Medical Research and Opinion, 26, 2183-2191. https://doi.org/10.1185/03007995.2010.506375
Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., et al. (2011) Characteristics of Patients with Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 9, 428-433. https://doi.org/10.1016/j.cgh.2011.01.023
Bianchini, F., Kaaks, R. and Vainio, H. (2002) Overweight, Obesity, and Cancer Risk. The Lancet Oncology, 3, 565-574. https://doi.org/10.1016/S1470-2045(02)00849-5
Park, E.J., Lee, J.H., Yu, G.Y., He, G., Ali, S.R., Holzer, R.G., et al. (2010) Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression. Cell, 140, 197-208. https://doi.org/10.1016/j.cell.2009.12.052
Calle, E.E., Rodriguez, C., Walker-Thurmond, K. and Thun, M.J. (2003) Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. The New England Journal of Medicine, 348, 1625-1638. https://doi.org/10.1056/NEJMoa021423
Tournier, C. (2013) The 2 Faces of JNK Signaling in Cancer. Genes & Cancer, 4, 397-400. https://doi.org/10.1177/1947601913486349
Jiang, C.M., Pu, C.W., Hou, Y.H., Chen, Z., Alanazy, M. and Hebbard, L. (2014) Non Alcoholic Steatohepatitis a Precursor for Hepatocellular Carcinoma Development. World Journal of Gastroenterology, 20, 16464-16473. https://doi.org/10.3748/wjg.v20.i44.16464
Schmidt-Arras, D. and Rose-John, S. (2016) IL-6 Pathway in the Liver: From Physiopathology to Therapy. Journal of Hepatology, 64, 1403-1415. https://doi.org/10.1016/j.jhep.2016.02.004
Jiang, N., Sun, R. and Sun, Q. (2014) Leptin Signaling Molecular Actions and Drug Target in Hepatocellular Carcinoma. Drug Design, Development and Therapy, 8, 2295-2302.
Sharma, D., Wang, J., Fu, P.P., Sharma, S., Nagalingam, A., Mells, J., et al. (2010) Adiponectin Antagonizes the Oncogenic Actions of Leptin in Hepatocellular Carcinogenesis. Hepatology, 52, 1713-1722. https://doi.org/10.1002/hep.23892
Maximos, M., Bril, F., Portillo, S.P., Lomonaco, R., Orsak, B., Biernacki, D., et al. (2015) The Role of Liver Fat and Insulin Resistance as Determinants of Plasma Aminotransferase Elevation in Nonalcoholic Fatty Liver Disease. Hepatology, 61, 153-160. https://doi.org/10.1002/hep.27395
Cusi, K. (2016) Treatment of Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: Current Approaches and Future Directions. Diabetologia, 59, 1112-1120. https://doi.org/10.1007/s00125-016-3952-1
Starley, B.Q., Calcagno, C.J. and Harrison, S.A. (2010) Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection. Hepatology, 51, 1820-1832. https://doi.org/10.1002/hep.23594
Chun, Y.S., Huang, M., Rink, L. and Von Mehren, M. (2014) Expression Levels of Insulin-Like Growth Factors and Receptors in Hepatocellular Carcinoma: A Retrospective Study. World Journal of Surgical Oncology, 12, 231. https://doi.org/10.1186/1477-7819-12-231
Mouzaki, M., Comelli, E.M., Arendt, B.M., Bonengel, J., Fung, S.K., Fischer, S.E., et al. (2013) Intestinal Microbiota in Patients with Nonalcoholic Fatty Liver Disease. Hepatology, 58, 120-127. https://doi.org/10.1002/hep.26319
Zhu, L., Baker, S.S., Gill, C., Liu, W., Alkhouri, R., Baker, R.D., et al. (2013) Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection between Endogenous Alcohol and NASH. Hepatology, 57, 601-609. https://doi.org/10.1002/hep.26093
Schloss, P.D. and Handelsman, J. (2004) Status of the Microbial Census. Microbiology and Molecular Biology Reviews, 68, 686-691. https://doi.org/10.1128/MMBR.68.4.686-691.2004
Vyas, U. and Ranganathan, N. (2012) Probiotics, Prebiotics, and Synbiotics: Gut and Beyond. Gastroenterology Research and Practice, 2012, Article ID: 872716. https://doi.org/10.1155/2012/872716
Koropatkin, N.M., Cameron, E.A. and Martens, E.C. (2012) How Glycan Metabolism Shapes the Human Gut Microbiota. Nature Reviews Microbiology, 10, 323-335. https://doi.org/10.1038/nrmicro2746
Bull, M.J. and Plummer, N.T. (2014) Part 1: The Human Gut Microbiome in Health and Disease. Integrative Medicine (Encinitas), 13, 17-22.
Vanni, E. and Bugianesi, E. (2009) The Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: Another Pathway to Insulin Resistance? Hepatology, 49, 1790-1792. https://doi.org/10.1002/hep.23036
Sanduzzi, Z.M., Rocco, A., Compare, D. and Nardone, G. (2017) The Gut Microbiota: A New Potential Driving Force in Liver Cirrhosis and Hepatocellular Carcinoma. United European Gastroenterology Journal, 5, 944-953. https://doi.org/10.1177/2050640617705576
Compare, D., Coccoli, P., Rocco, A., Nardone, O.M., De Maria, S., Carteni, M., et al. (2012) Gut-Liver Axis: The Impact of Gut Microbiota on Non Alcoholic Fatty Liver Disease. Nutrition, Metabolism and Cardiovascular Diseases, 22, 471-476. https://doi.org/10.1016/j.numecd.2012.02.007
Zhang, H.Y., Han, D.W., Su, A.R., Zhang, L.T., Zhao, Z.F., Ji, J.Q., et al. (2007) Intestinal Endotoxemia Plays a Central Role in Development of Hepatopulmonary Syndrome in a Cirrhotic Rat Model Induced by Multiple Pathogenic Factors. World Journal of Gastroenterology, 13, 6385-6395. https://doi.org/10.3748/wjg.v13.i47.6385
Ruiz, A.G., Casafont, F., Crespo, J., Cayon, A., Mayorga, M., Estebanez, A., et al. (2007) Lipopolysaccharide-Binding Protein Plasma Levels and Liver TNF-Alpha Gene Expression in Obese Patients: Evidence for the Potential Role of Endotoxin in the Pathogenesis of Non-Alcoholic Steatohepatitis. Obesity Surgery, 17, 1374-1380. https://doi.org/10.1007/s11695-007-9243-7
Borrelli, A., Bonelli, P., Tuccillo, F.M., Goldfine, I.D., Evans, J.L., Buonaguro, F.M., et al. (2018) Role of Gut Microbiota and Oxidative Stress in the Progression of Non-Alcoholic Fatty Liver Disease to Hepatocarcinoma: Current and Innovative Therapeutic Approaches. Redox Biology, 15, 467-479. https://doi.org/10.1016/j.redox.2018.01.009
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., et al. (2017) Development of Hepatocellular Carcinoma in Japanese Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease: Association between PNPLA3 Genotype and Hepatocarcinogenesis/Fibrosis Progression. Hepatology Research, 47, 1083-1092. https://doi.org/10.1111/hepr.12840
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. (2008) Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease. Nature Genetics, 40, 1461-1465. https://doi.org/10.1038/ng.257
Pirazzi, C., Valenti, L., Motta, B.M., Pingitore, P., Hedfalk, K., Mancina, R.M., et al. (2014) PNPLA3 Has Retinyl-Palmitate Lipase Activity in Human Hepatic Stellate Cells. Human Molecular Genetics, 23, 4077-4085. https://doi.org/10.1093/hmg/ddu121
Huang, Y., Cohen, J.C. and Hobbs, H.H. (2011) Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease. The Journal of Biological Chemistry, 286, 37085-37093. https://doi.org/10.1074/jbc.M111.290114
Pingitore, P., Pirazzi, C., Mancina, R.M., Motta, B.M., Indiveri, C., Pujia, A., et al. (2014) Recombinant PNPLA3 Protein Shows Triglyceride Hydrolase Activity and Its I148M Mutation Results in Loss of Function. Biochimica et Biophysica Acta, 1841, 574-580. https://doi.org/10.1016/j.bbalip.2013.12.006
Pirazzi, C., Adiels, M., Burza, M.A., Mancina, R.M., Levin, M., Stahlman, M., et al. (2012) Patatin-Like Phospholipase Domain-Containing 3 (PNPLA3) I148M (rs738409) Affects Hepatic VLDL Secretion in Humans and in Vitro. Journal of Hepatology, 57, 1276-1282. https://doi.org/10.1016/j.jhep.2012.07.030
Fields, A.L., Soprano, D.R. and Soprano, K.J. (2007) Retinoids in Biological Control and Cancer. Journal of Cellular Biochemistry, 102, 886-898. https://doi.org/10.1002/jcb.21530
Sookoian, S., Castano, G.O. and Pirola, C.J. (2015) PNPLA3 I148M Variant Is Associated with Metabolic Stress-Response Phenotype in Patients with Nonalcoholic Fatty Liver Disease. Hepatology, 61, 1769. https://doi.org/10.1002/hep.27390
Streba, L.A., Vere, C.C., Rogoveanu, I. and Streba, C.T. (2015) Nonalcoholic Fatty Liver Disease, Metabolic Risk Factors, and Hepatocellular Carcinoma: An Open Question. World Journal of Gastroenterology, 21, 4103-4110. https://doi.org/10.3748/wjg.v21.i14.4103
Tsuchiya, N., Sawada, Y., Endo, I., Saito, K., Uemura, Y. and Nakatsura, T. (2015) Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. World Journal of Gastroenterology, 21, 10573-10583. https://doi.org/10.3748/wjg.v21.i37.10573
Bruix, J. and Sherman, M. (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology, 53, 1020-1022. https://doi.org/10.1002/hep.24199
European Association for the Study of The Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 56, 908-943. https://doi.org/10.1016/j.jhep.2011.12.001
Chan, S.L., Mo, F.K., Johnson, P.J., Hui, E.P., Ma, B.B., Ho, W.M., et al. (2009) New Utility of an Old Marker: Serial Alpha-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients with Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. Journal of Clinical Oncology, 27, 446-452. https://doi.org/10.1200/JCO.2008.18.8151
de Lope, C.R., Tremosini, S., Forner, A., Reig, M. and Bruix, J. (2012) Management of HCC. Journal of Hepatology, 56, S75-S87. https://doi.org/10.1016/S0168-8278(12)60009-9
Omata, M., Cheng, A.L., Kokudo, N., Kudo, M., Lee, J.M., Jia, J., et al. (2017) Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: A 2017 Update. Hepatology International, 11, 317-370. https://doi.org/10.1007/s12072-017-9799-9
Carr, B.I., Guerra, V., Giannini, E.G., Farinati, F., Ciccarese, F., Rapaccini, G.L., et al. (2014) Low Alpha-Fetoprotein HCC and the Role of GGTP. The International Journal of Biological Markers, 29, e395-e402. https://doi.org/10.5301/jbm.5000092
Mita, Y., Aoyagi, Y., Yanagi, M., Suda, T., Suzuki, Y. and Asakura, H. (1998) The Usefulness of Determining Des-Gamma-Carboxy Prothrombin by Sensitive Enzyme Immunoassay in the Early Diagnosis of Patients with Hepatocellular Carcinoma. Cancer, 82, 1643-1648. https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9 3.0.CO;2-B
Okuda, H., Nakanishi, T., Takatsu, K., Saito, A., Hayashi, N., Watanabe, K., et al. (1999) Measurement of Serum Levels of Des-Gamma-Carboxy Prothrombin in Patients with Hepatocellular Carcinoma by a Revised Enzyme Immunoassay Kit with Increased Sensitivity. Cancer, 85, 812-818. https://doi.org/10.1002/(SICI)1097-0142(19990215)85:4 3.0.CO;2-O
Higashi, T., Hasegawa, K., Kokudo, N., Makuuchi, M., Izumi, N., Ichida, T., et al. (2011) Demonstration of Quality of Care Measurement Using the Japanese Liver Cancer Registry. Hepatology Research, 41, 1208-1215. https://doi.org/10.1111/j.1872-034X.2011.00880.x
Yu, R., Tan, Z., Xiang, X., Dan, Y. and Deng, G. (2017) Effectiveness of PIVKA-II in the Detection of Hepatocellular Carcinoma Based on Real-World Clinical Data. BMC Cancer, 17, 608. https://doi.org/10.1186/s12885-017-3609-6
Saitta, C., Raffa, G., Alibrandi, A., Brancatelli, S., Lombardo, D., Tripodi, G., et al. (2017) PIVKA-II Is a Useful Tool for Diagnostic Characterization of Ultrasound-Detected Liver Nodules in Cirrhotic Patients. Medicine (Baltimore), 96, e7266. https://doi.org/10.1097/MD.0000000000007266